HHM Wealth Advisors LLC Boosts Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

HHM Wealth Advisors LLC boosted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 135.8% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 191 shares of the company’s stock after purchasing an additional 110 shares during the quarter. HHM Wealth Advisors LLC’s holdings in IDEXX Laboratories were worth $93,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in IDXX. Private Advisor Group LLC grew its position in shares of IDEXX Laboratories by 13.5% in the 4th quarter. Private Advisor Group LLC now owns 2,189 shares of the company’s stock valued at $1,215,000 after buying an additional 261 shares during the last quarter. NBC Securities Inc. grew its holdings in shares of IDEXX Laboratories by 5.2% during the fourth quarter. NBC Securities Inc. now owns 582 shares of the company’s stock worth $323,000 after purchasing an additional 29 shares during the last quarter. QRG Capital Management Inc. increased its position in shares of IDEXX Laboratories by 7.6% during the fourth quarter. QRG Capital Management Inc. now owns 3,467 shares of the company’s stock worth $1,924,000 after purchasing an additional 245 shares in the last quarter. Checchi Capital Advisers LLC lifted its holdings in shares of IDEXX Laboratories by 12.0% in the 4th quarter. Checchi Capital Advisers LLC now owns 673 shares of the company’s stock valued at $374,000 after purchasing an additional 72 shares during the last quarter. Finally, Avantax Advisory Services Inc. lifted its holdings in shares of IDEXX Laboratories by 21.1% in the 4th quarter. Avantax Advisory Services Inc. now owns 632 shares of the company’s stock valued at $351,000 after purchasing an additional 110 shares during the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

IDXX has been the topic of a number of research reports. StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, July 10th. Stifel Nicolaus reduced their target price on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a report on Monday, June 24th. BTIG Research initiated coverage on IDEXX Laboratories in a report on Thursday, July 25th. They set a “buy” rating and a $580.00 price target on the stock. Finally, Piper Sandler dropped their price target on IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 14th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $582.25.

IDEXX Laboratories Trading Down 1.1 %

NASDAQ IDXX opened at $490.26 on Thursday. The company has a quick ratio of 1.03, a current ratio of 1.37 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $40.49 billion, a P/E ratio of 47.46, a P/E/G ratio of 4.02 and a beta of 1.33. IDEXX Laboratories, Inc. has a 52-week low of $372.50 and a 52-week high of $583.39. The firm has a 50-day moving average price of $480.50 and a 200 day moving average price of $502.25.

IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, August 6th. The company reported $2.44 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.88 by ($0.44). IDEXX Laboratories had a return on equity of 57.03% and a net margin of 22.34%. The business had revenue of $1 billion for the quarter, compared to analysts’ expectations of $1.01 billion. During the same period last year, the company posted $2.67 earnings per share. The business’s quarterly revenue was up 6.4% on a year-over-year basis. Equities research analysts expect that IDEXX Laboratories, Inc. will post 10.45 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.